DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 020711/S-026 and S-035

SUPPLEMENT APPROVAL

SmithKline Beecham Corporation
d/b/a GlaxoSmithKline
5 Moore Drive
Research Triangle Park, NC 27709

Attention: Mary E. Martinson
Senior Director, Psychiatry
U.S. Regulatory Affairs

Dear Ms. Martinson:

Please refer to your Supplemental New Drug Applications (sNDAs) dated January 31, 2006 (S-026), and October 18, 2010 (S-035), received February 1, 2006, and October 18, 2010, respectively, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Zyban (bupropion hydrochloride) Sustained-Release Tablets.

We acknowledge receipt of your amendments dated June 6 and 10, 2011.

The June 6, 2011, submission constituted a complete response to our August 1, 2006, action letter for supplement S-026.

These supplemental new drug applications propose the following changes to the package insert:

S-026: Revisions to the **CLINICAL PHARMACOLOGY**: **Pharmacokinetics: Absorption** sections based upon a food effect study.

S-035: **CLINICAL PHARMACOLOGY: Metabolism** and **PRECAUTIONS: Drug Interactions**-Addition of pharmacokinetic information from a study of healthy volunteers taking efavirenz and bupropion.

PRECAUTIONS: Drug Interactions-Statement deleted as a number of drug interaction studies have been conducted providing data on the metabolism of bupropion following concomitant administration of other drugs or the effect of concomitant administration of bupropion on the metabolism of other drugs.

PRECAUTIONS: Drugs Metabolized by Cytochrome P450IID6 (CYP2D6)- Addition of a statement regarding reduced efficacy of drugs which require metabolic activation by CYP2D6 when administered concomitantly with inhibitors of CYP2D6, such as bupropion.

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert and Medication Guide), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Ayanna Augustus, Ph.D., Regulatory Project Manager, at (301) 301-796-3890.

Sincerely,

{See appended electronic signature page}

Bob A. Rappaport, M.D.
Director
Division of Anesthesia, Analgesia,
and Addiction Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

BOB A RAPPAPORT
08/22/2011